Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest announcement is out from ImmuPharma ( (GB:IMM) ).
ImmuPharma PLC has announced the promotion of Dr. Sébastien Goudreau to Chief Scientific Officer and Dr. Laura Mauran-Ambrosino to Head of Research and Development, coinciding with the filing of a new patent for their lead asset, P140. These appointments are seen as pivotal for the company’s strategy to partner and commercialize its product portfolio, particularly P140, highlighting the importance of having a strong R&D team for future commercial negotiations.
More about ImmuPharma
ImmuPharma PLC is a specialty biopharmaceutical company that focuses on discovering and developing peptide-based therapeutics. The company’s portfolio includes novel peptide therapeutics targeting autoimmune diseases and anti-infectives.
Average Trading Volume: 2,184,678
Technical Sentiment Signal: Sell
Current Market Cap: £11.12M
Learn more about IMM stock on TipRanks’ Stock Analysis page.